Zobrazeno 1 - 10 of 166 pro vyhledávání: '"B Lucci"'
1
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
Autor: Edward Shelton, Ashwin N. Ananthakrishnan, Jenny Sauk, John J. Garber, Cosmas Giallourakis, Sonia Friedman, Punyaganie de Silva, Jessica R. Allegretti, Betsy W. Stevens, Fredrick Makrauer, Matthew J. Hamilton, Jonathan S. Levine, Deanna D. Nguyen, Joshua R. Korzenik, Michal Tomczak, Hamed Khalili, Robert Burakoff, Vijay Yajnik, Matthew B. Lucci
Publikováno v: Inflammatory Bowel Diseases. 21:2879-2885
Background Vedolizumab (VDZ) demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of VDZ at week 14 in inflammatory bowel disease in a multicenter cohort of patients. Met
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452c13be97853a3527426178796ee0a3
https://doi.org/10.1097/mib.0000000000000561
Zobrazit plný text záznamu
2
Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease
Autor: Joshua R. Korzenik, Danielle Emmons, Brian Vogel, Emily Collins, Lawrence F. Borges, Emily Arthur, Bonnie Cao, Matthew B. Lucci, Matthew S. Chang, Jessica R. Allegretti
Publikováno v: Inflammatory Bowel Diseases. 21:2583-2589
Background Care of patients with inflammatory bowel disease (IBD) poses a significant burden to the health-care system. Repeat hospitalization in subgroups of IBD patients seems to be a large part of this issue; however, there are limited data examin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792843fea0e75b19e3dd7744d264540d
https://doi.org/10.1097/mib.0000000000000537
Zobrazit plný text záznamu
3
Fits of weeping as an unusual manifestation of reflex epilepsy induced by speaking: case report
Autor: D Romito, E Del Zotto, C Marchini, B Lucci
Publikováno v: Acta Neurologica Scandinavica. 90:218-221
We report the case of a 62-year-old man with no past CNS history who for some weeks had had fits of weeping that lasted from 30" to 3', precede by any aura; sensorium was clear; there were no symptoms of any kind after the paroxysm; in the course of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42f52a0d81aa65eaac5f066d78a228b
https://doi.org/10.1111/j.1600-0404.1994.tb02709.x
Zobrazit plný text záznamu
4
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
Autor: Bernard Burnand, Harry Sokol, Pascal Juillerat, Matthew B. Lucci, Florian Froehlich, Jacques Cosnes, Laurent Beaugerie, Vijay Yajnik, Andrew J. Macpherson, Joshua R. Korzenik
Publikováno v: Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 2014, 21 (1), pp.60-70. ⟨10.1097/MIB.0000000000000225⟩
Inflammatory Bowel Diseases, Lippincott, Williams & Wilkins, 2014, 21 (1), pp.60-70. ⟨10.1097/MIB.0000000000000225⟩
BACKGROUND: Infliximab (IFX) has been used for over a decade worldwide. Less is known about the natural history of IFX use beyond a few years and which patients are more likely to sustain benefits. METHODS: Patients with Crohn's disease (CD) exposed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0147e3e2c2675ac1f28ad43d87166a3
https://hal.science/hal-01097180
Zobrazit plný text záznamu
5
Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease
Autor: Jonathan S. Levine, Jessica R. Allegretti, Matthew B. Lucci, Andrew M. Courtwright, Joshua R. Korzenik
Background The prevalence and perceived effectiveness of marijuana use has not been well studied in inflammatory bowel disease (IBD) despite increasing legal permission for its use in Crohn's disease. Health care providers have little guidance about
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447f794dcd9a5329953781b956450940
https://europepmc.org/articles/PMC4126607/
Zobrazit plný text záznamu
6
Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study
Autor: Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C, Bomprezzi R, Di Giovanni S, Figa` Talamanca L, Nistico L, Fagnani C, Neale MC, Cascino I, Giorgi G, Battaglia MA, Buttinelli C, Tosi R, Salvetti M, M. Melato, R. Dellantonio, L. Sironi, E. Bottacchi, M. Signorino, R. Angeloni, L. Curatola, C. Paci, M. Ragno, G. Sirocchi, AM. Vurchio, E. Duc, D. Spitaleri, M. Trojano, M. Liguori, N. Cimini, G. Moretto, M. Porta, MR Rottoli A. Mamoli, M. Camerlingo, E. Nardozza, T. Sacquegna, S. Stecchi, C. Scandellari, L. Callea, R. Capra, M. Codella, M. G. Marrosu, E. Cocco, A. Spissu, G. Cossu, S. Tronci, A. Di Lauro, E. Lombardi, A. Reggio, F. Patti, P. Valentino, A. Quattrone, D Farina, M. E. Nives, A. Lugaresi, F. Perla, M. G. Rosso, M. R. Tola, E. Granieri, MP Amato L. Massacesi, E. Millefiorini, V. Durastanti, G. L. Mancardi, A. Murialdo, NR. Pizio, P. Bellantonio, R. Fantozzi, R. Totaro, A. Carolei, F. Giramma, A. T. Lazzaro, C. Giraldi, M. Mazzoni, G. Giuliani, E. Pucci, P. Previdi, MC. Fazio, M. Buccafusca, P. Girlanda, C. Messina, G. D’Aleo, C. Milanese, L. Lamantia, D. Caputo, E. Scarpini, R. Clerici, L. Moiola, M. Gironi, E. Merelli, F. Casoni, S. Bonavita, G. Tedeschi, M. Leone, D. Mittino, SB. Murgia, L. Musu, P. Gallo, P. Perini, E. Frasson, G. Salemi, G. Cuccia, E. Montanari, L. Manneschi, D. Saviola, M. Antonelli, V. Cosi, R. Bergamaschi, V. Gallai, D. Murasecco, P. Sarchielli, R. Urcioli, G. Perticoni, G. Meucci, G. Moscato, B. Lucci, E. Covezzi, MG. Coniglio, D. Acquistapace, L. Motti, B. Dossi Curro`, M. Frontoni, C. Mainero, P. Giannetti, I. Pestalozza, S. Di Legge, M. Spadaro, C. Pozzilli, S. Romano, B. Mercuri, C. Scoppetta, C. Gasperini, S. Galgani, MG. Grasso, S. Paolucci, PA. Tonali, A. Leonardi, A. Oneto, G Rosati, M. A. Sotgiu, A. Bertolotto, M. Capobianco, L. Durelli, M. Clerico, L. Sosso, R. Bongioanni, D. Orrico, C. Carbonin, U. Freo. M. Zaffaroni, A. Ghezzi, N. Falcone
Publikováno v: Annals of neurology 59 (2006): 27–34. doi:10.1002/ana.20683
info:cnr-pdr/source/autori:Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C,Bomprezzi R, Di Giovanni S, Figa Talamanca L, Nistico L, Fagnani C, Neale MC, Cascino I, Giorgi G, Battaglia MA, Buttinelli C, Tosi R, Salvetti M./titolo:Multiple Sclerosis in Twins from Continental Italy and Sardinia: A Nationwide Study/doi:10.1002%2Fana.20683/rivista:Annals of neurology/anno:2006/pagina_da:27/pagina_a:34/intervallo_pagine:27–34/volume:59
Knowledge about the balance between heritable and nonheritable risk in multiple sclerosis (MS) is based on twin studies in high-prevalence areas. In a study that avoided ascertainment limitations and directly compared continental Italy (medium-preval
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::453c8b93c6b3690e3a79b1c0fd47ccd4
http://hdl.handle.net/11570/1943231
Zobrazit plný text záznamu
7
High Intensity Exercise Promotes Escape of Adrenocorticotropin and Cortisol from Suppression by Dexamethasone: Sexually Dimorphic Responses1
Autor: George P. Chrousos, John S. Petrides, Philip W. Gold, Patricia A. Deuster, Anita Singh, Edward B. Lucci
Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 83:3332-3338
Exercise promotes escape of ACTH and cortisol from suppression by dexamethasone (DEX) in some healthy men and women. To determine whether stimulus strength, diurnal rhythmicity, or gender influences neuroendocrine escape during DEX suppression, we st
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9950e898321844bb28e58170d3409c8
https://doi.org/10.1210/jcem.83.9.5110
Zobrazit plný text záznamu
9
Sa1198 Initial Vedolizumab Cohort: Patient Characteristics and Clinical Response
Autor: Michael Currier, Beth-Ann Norton, Bonnie Cao, Matthew B. Lucci, Justine States, Emily Collins, Anne Marie Crowell, Madeline Carrellas, Joshua R. Korzenik
Publikováno v: Gastroenterology. 148:S-255
Background: Vedolizumab, an α4β7 integrin antibody, was recently approved for use in Crohn's disease (CD) and ulcerative colitis (UC). Characteristics of patients with inflammatory bowel disease (IBD) who receive vedolizumab in clinical practice, a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49bed983618f6061ead6f9ca6f671032
https://doi.org/10.1016/s0016-5085(15)30838-6
Zobrazit plný text záznamu
10
Sa1247 Risk Factors for Re-Hospitalization Within 90 Days in Patients With Inflammatory Bowel Disease Are Not Related to Disease Activity
Autor: Emily Collins, Emily Arthur, Danielle Emmons, Brian Vogel, Joshua R. Korzenik, Matthew S. Chang, Lawrence F. Borges, Jessica R. Allegretti, Bonnie Cao, Matthew B. Lucci
Publikováno v: Gastroenterology. 148:S-269
Background: Previous studies have demonstrated that the care of inflammatory bowel disease (IBD) patients poses a significant burden to the healthcare system. More than one and a half million people in the United States suffer from ulcerative colitis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8d65ee5ae074b623ad176e0356b645b
https://doi.org/10.1016/s0016-5085(15)30887-8
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje